Cancer Therapy India: Drugmaker Eli Lilly and Company India has launched TanStrive, a new targeted therapy for cancer patients. This drug is specifically designed for patients with certain types of cancer.

new cancer drug

New Cancer Drug Launched In India: A new hope has emerged in India regarding cancer treatment. Drug manufacturing company Eli Lilly and Company India has launched a new targeted therapy, TanStrive, for cancer patients. This drug has been developed for a specific type of cancer patients in whom RET gene alteration is found. The company claims that this drug works by blocking the abnormal signals that promote cancer. However, it is important to understand that it has not been claimed that a 14-day dose will completely eliminate cancer in every patient. 14 days is just the treatment cycle of one box of this drug.

For which patients is this medicine?

This drug is intended for patients with locally advanced or metastatic solid tumors whose cancer is linked to a RET gene alteration. This means it's not suitable for all types of cancer. Before starting treatment, doctors perform tests to determine whether a patient has a RET gene alteration.

How does the new drug work?

According to the company, TanStrive is designed to directly target the RET gene alteration. It blocks the abnormal signaling pathways that cause cancer cells to grow rapidly. It is an oral medication that patients take twice daily. The medication is available in 40 mg, 80 mg, 120 mg, and 160 mg tablets, allowing doctors to customize the dosage based on patient needs.

What is the cost of 14 days' medicine?

The company has priced this drug at ₹2.15 lakh per box. Each box contains the medication needed for 14 days of treatment. The length of time patients will need to take the medication after this depends on their illness and their doctor's advice.

What did the company say?

Winslow Tucker, President and General Manager of Eli Lilly and Company India, said that precision oncology is rapidly changing the way cancer is treated. According to him, TanStrive is an important step towards increasing access to targeted therapy for patients in India whose cancer is linked to RET gene alterations. It is important to understand that this new drug cannot be considered a cure for every cancer patient; it is only for those patients with RET gene alterations. Therefore, it is crucial to consult an oncologist and undergo necessary testing before starting any treatment.